Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Preoperative Continuation Versus Interruption of Oral Hypoglycemics in Type 2 Diabetic Patients Undergoing Ambulatory Surgery: A Randomized Controlled Trial.

Gasanova I, Meng J, Minhajuddin A, Melikman E, Alexander JC, Joshi GP.

Anesth Analg. 2018 Oct;127(4):e54-e56. doi: 10.1213/ANE.0000000000003675.

PMID:
30044293
2.

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

Ann Intern Med. 2008 Oct 21;149(8):531-9.

PMID:
18936501
3.

Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.

Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S; Study 05 Group.

Diabetes Care. 2015 Mar;38(3):365-72. doi: 10.2337/dc14-0666. Epub 2015 Jan 15.

PMID:
25592197
4.

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.

Diabetes Obes Metab. 2009 Feb;11(2):157-66. doi: 10.1111/j.1463-1326.2008.00994.x. Erratum in: Diabetes Obes Metab. 2009 Apr;11(4):405.

PMID:
19125777
6.

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.

Simó R, Guerci B, Schernthaner G, Gallwitz B, Rosas-Guzmàn J, Dotta F, Festa A, Zhou M, Kiljański J.

Cardiovasc Diabetol. 2015 Sep 4;14:116. doi: 10.1186/s12933-015-0279-z.

7.

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.

Diabetes Care. 2005 Feb;28(2):254-9.

PMID:
15677775
9.

[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].

Seufert J.

Dtsch Med Wochenschr. 2014 Feb;139 Suppl 2:S65-9. doi: 10.1055/s-0033-1359993. Epub 2014 Jan 30. Review. German. No abstract available.

PMID:
24481635
10.

Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).

Pratley RE, Urosevic D, Boldrin M, Balena R; T-emerge 6 Study Group.

Diabetes Obes Metab. 2013 Mar;15(3):234-40. doi: 10.1111/dom.12009. Epub 2012 Sep 30.

PMID:
22958426
11.

Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.

Hong AR, Lee J, Ku EJ, Hwangbo Y, Kim KM, Moon JH, Choi SH, Jang HC, Lim S.

Diabetes Res Clin Pract. 2015 Jul;109(1):141-8. doi: 10.1016/j.diabres.2015.04.019. Epub 2015 May 5.

PMID:
26003889
12.

Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes.

Demma LJ, Carlson KT, Duggan EW, Morrow JG 3rd, Umpierrez G.

J Clin Anesth. 2017 Feb;36:184-188. doi: 10.1016/j.jclinane.2016.10.003. Epub 2016 Dec 5.

PMID:
28183563
13.

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.

Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, Millington D, Vercruysse F, Canovatchel W, Meininger G.

Diabetes Care. 2015 Mar;38(3):355-64. doi: 10.2337/dc13-2762. Epub 2014 Sep 9.

PMID:
25205142
14.

Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.

González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, Wacher-Rodarte N, Martínez-Abundis E, Aguilar-Salinas C, Islas-Andrade S, Arechavaleta-Granell R, González-Canudas J, Rodríguez-Morán M, Zavala-Suárez E, Ramos-Zavala MG, Metha R, Revilla-Monsalve C, Beltrán-Jaramillo TJ.

J Diabetes Complications. 2009 Nov-Dec;23(6):376-9. doi: 10.1016/j.jdiacomp.2008.09.002. Epub 2008 Oct 11.

PMID:
18849173
15.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
16.

The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.

McAlister FA, Eurich DT, Majumdar SR, Johnson JA.

Eur J Heart Fail. 2008 Jul;10(7):703-8. doi: 10.1016/j.ejheart.2008.05.013. Epub 2008 Jun 19.

17.

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.

Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M, Fisher SA.

Diabetes Obes Metab. 2014 May;16(5):443-50. doi: 10.1111/dom.12234. Epub 2013 Dec 8.

PMID:
24205943
18.

Empagliflozin/metformin (Synjardy) for type 2 diabetes.

[No authors listed]

Med Lett Drugs Ther. 2015 Dec 21;57(1484):172-4. No abstract available.

PMID:
26670554
19.

The UK Prospective Diabetes Study.

Evans M.

Lancet. 1998 Dec 12;352(9144):1932-3; author reply 1934. No abstract available.

PMID:
9863807
20.

The UK Prospective Diabetes Study.

Bailey CJ, Grant PJ.

Lancet. 1998 Dec 12;352(9144):1932; author reply 1934. No abstract available.

PMID:
9863806

Supplemental Content

Support Center